न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015 (ivr-180)); influenza virus a/switzerland/8060/2017 (h3n2) like strain 15ug (a/brisbane/1/2018 (x-311)); influenza virus b/phuket/3073/2013 - like strain 15ug ( b/phuket/3073/2013 (bvr-1b)) - suspension for injection - 45 mcg/0.5ml - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015 (ivr-180)) influenza virus a/switzerland/8060/2017 (h3n2) like strain 15ug (a/brisbane/1/2018 (x-311)) influenza virus b/phuket/3073/2013 - like strain 15ug ( b/phuket/3073/2013 (bvr-1b)) excipient: calcium chloride dihydrate citric acid monohydrate dibasic sodium phosphate dihydrate magnesium chloride hexahydrate monobasic potassium phosphate polysorbate 80 potassium chloride sodium chloride sodium citrate dihydrate sorbitan trioleate squalene water for injection - active immunisation against influenza in the elderly (65 years of age and older), especially for those with an increased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases). the use of fluad should be based on official recommendations.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing); influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing); influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) - suspension for injection - 15 mcg - active: influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing) influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing) influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - influenza virus (nh) a/california/7/2009 (h1n1)pdm09-derived strain - injection, suspension - 15 mcg ha/0.1ml

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/victoria/361/2011 (h3n2) recombinant hemagglutinin antigen (unii: k5313h4vgs) (influenza a virus a/victoria/361/2011 (h3n2) recombinant hemagglutinin antigen - unii:k5313h4vgs), influenza b virus b/wisconsin/1/2010 recombinant hemagglutinin antigen (unii: n9c76986u2) (influenza b virus b/wisco - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen 45 ug in 0.5 ml - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 through 49 years of age. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis), to any component of the vaccine (see description [11]).  reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to flublok. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this vaccine should be used during pregnancy only if clearly needed. the effect of flublok on embryo-fetal and pre-weaning development was evaluated in pregnant rats. animals were administered flublok by intramuscular injection twice prior to gestation and once during the period of organ

इसराइल - अंग्रेज़ी - Ministry of Health

neopharm scientific ltd - a/california/7/2009 (h1n1)pdm09-like virus; a/hong kong/4801/2014 (h3n2) - like virus; b/brisbane/60/2008 - like virus - suspension for injection - b/brisbane/60/2008 - like virus 15 mcg / 0.5 ml; a/hong kong/4801/2014 (h3n2) - like virus 15 mcg / 0.5 ml; a/california/7/2009 (h1n1)pdm09-like virus 15 mcg / 0.5 ml - vaccinia immunoglobulin - vaccinia immunoglobulin - active immunisation against influenza in the elderly (65 years of age and over), especially for those with an infreased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).

इसराइल - अंग्रेज़ी - Ministry of Health

neopharm scientific ltd - a/california/7/2009 (h1n1) 7.5 mcg / 0.5 ml - suspension for injection - influenza, inactivated, whole virus - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

इसराइल - अंग्रेज़ी - Ministry of Health

neopharm scientific ltd - a/california/7/2009 (h1n1) 7.5 mcg / 0.5 ml - suspension for injection - influenza, inactivated, whole virus - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

इसराइल - अंग्रेज़ी - Ministry of Health

glaxo smith kline (israel) ltd - a/california/7/2009 (h1n1) 15 mcg / 0.5 ml; a/victoria/361/2011 (h3n2) 15 mcg / 0.5 ml - suspension for injection - influenza, live attenuated - prophylaxis of influenza, especially those who run an increased risk of associated complications. fluarix is indicated in adults and children from 6 months of age.

इसराइल - अंग्रेज़ी - Ministry of Health

glaxo smith kline (israel) ltd - a/california/7/2009 (h1n1)v nymc x-179a 3.75 mcg / 0.25 ml - suspension for injection - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - influenza virus (nh) a/california/7/2009 (h1n1)pdm09 - like strain - injection - 15 mcg haemagglutinin/0.5 ml